Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution

– ARCALYST^® (rilonacept) Q1 2025 net product revenue of $137.8 million, representing 75% year-over-year growth –
– ARCALYST 2025 expected net product revenue increased to $590 - $605 million –
– KPL-387 Phase 2/3 clinical trial in recurrent pericarditis on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 –
– Current operating plan expected to remain cash flow positive on an annual basis –
– Conference call and webcast scheduled for 8:30 am ET today –